Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.67 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.57 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.57 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.57 |
| ▸ | TK2 | O00142 | 2/20 | 0.51 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.51 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.48 |
| ▸ | NT5E | P21589 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3071099 | 0.90 | PYGM (0.55) | PYGMP2RY6P2RY2P2RY4TK2 | |
| SCHEMBL4959490 | 0.86 | PYGM (0.53) | PYGMP2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL2400429 | 0.85 | DNPH1 (0.50) | PYGMP2RY6TK2DNPH1P2RY14 | |
| SCHEMBL6839685 | 0.83 | PYGM (0.81) | PYGMP2RY6P2RY2P2RY4TK2 | |
| SCHEMBL3469958 | 0.82 | DNPH1 (0.74) | PYGMP2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL7152602 | 0.82 | PYGM (0.67) | PYGMP2RY6P2RY2P2RY4TK2 | |
| SCHEMBL9796913 | 0.82 | DNPH1 (0.74) | PYGMP2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL28372181 | 0.82 | DNPH1 (0.74) | PYGMP2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL6758925 | 0.82 | PYGM (0.97) | PYGMP2RY6P2RY2P2RY4TK2 | |
| SCHEMBL654693 | 0.82 | PYGM (0.97) | PYGMP2RY6P2RY2P2RY4TK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465734-B2 | Methods and compositions for overcoming resistance to biologic and chemotherapy | CELMED ONCOLOGY (USA), INC. (CA) | 2008-12-16 | — | — | US | claimed |
| EP-0217580-A2 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1987-04-08 | — | — | EP | claimed |
| EP-2054406-B1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | RESPROTECT GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| US-8492537-B2 | Nucleosides for suppressing or reducing the development of resistance in cytostatic therapy | RESPROTECT GMBH (DE) | 2013-07-23 | — | — | US | disclosed |
| US-20100227834-A1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | RESprotech GmbH (DE) | 2010-09-09 | — | — | US | disclosed |
| EP-2054406-A1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | RESprotect GmbH (DE) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008017515-A1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | RESPROTECT GMBH (DE) | 2008-02-14 | — | — | WO | disclosed |
| EP-1745061-A1 | NOVEL AMPHIPHILIC COMPOUNDS, PREPARATION METHOD THEREOF AND APPLICATIONS OF SAME | Universite D'Avignon et Des Pays Du Vaucluse (FR) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005116043-A1 | NOVEL AMPHIPHILIC COMPOUNDS, PREPARATION METHOD THEREOF AND APPLICATIONS OF SAME | UNIVERSITE D'AVIGNON ET DES PAYS DE VAUCLUSE (FR) | 2005-12-08 | — | — | WO | disclosed |
| US-5064946-A | 3-azido-2,3-dideoxy-B-D-erythro-pentofuranosyl derivatives of 4(1H)-pyrimidinones; antiretroviral, anti-AIDS | BURROUGHS WELLCOME CO. (US) | 1991-11-12 | — | — | US | disclosed |
| EP-0217580-A2 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1987-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227834-A1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | TYMP, ENTPD5, NTPCR | PYGM 1888/4885P2RY6 835/4885P2RY2 1321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.